Conference Track

Detection, Diagnosis, Screening, and Prevention

Source: CCO Independent Conference Coverage of the 2006 Annual San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Lymphovascular Invasion Strong Predictor of Positive Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
Recently Identified Human Mammary Tumor Virus May Explain Possible Causative Effect of Breast Cancer
β-tubulin III and IV Isoform Levels May Predict Overall Survival Rates in Metastatic Breast Cancer Patients After Treatment With Paclitaxel
Estrogen Receptor β Isoforms Shown to Have Prognostic Significance in Breast Cancer
Mammographic Breast Density Associated With Increased Risk of Breast Cancer Recurrence
High Breast Density Possibly an Important Predictor of Contralateral Breast Cancer Following Treatment for Ductal Carcinoma In Situ
Circulating Tumor Cells Positive for CK-19 and Mammaglobin-A mRNA Prognostic in Adjuvant Breast Cancer
Reducing Fat Intake Following Surgical Resection Can Improve Clinical Outcomes in Women With Breast Cancer
Benefit of Tamoxifen in Breast Cancer Prevention Confirmed in Long-Term IBIS-I Study Follow-up
Sonography a Viable Tumor Detection Method for Young Women With High Genetic Risk for Breast Cancer
Raloxifene May Not Have Same Effect on Incidence of in Situ Carcinomas as Tamoxifen
Presence of Persistent Disseminated Tumor Cells in Bone Marrow Predictive of Increased Risk of Relapse in Breast Cancer Patients

Expert Analysis

Detection, Diagnosis, Screening, and Prevention

Faculty:

William J. Gradishar, MD, FACP
Daniel F. Hayes, MD
Hope S. Rugo, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical trials for the treatment of breast cancer
Describe new techniques for the detection, screening, and prevention of breast cancer
Recall prognostic developments in the management of breast cancer treatment

CME CREDIT INFORMATION

Release Date: 02/08/07

Expiration Date: 02/07/08

Physicians: maximum of 1.75 AMA PRA Category 1 Credits™

Registered Nurses: 1.8 Nursing CE credits

Pharmacists: 1.8 contact hours (0.18 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.